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Abstract
Objectives. To assess whether modern management of RA has reduced the prescription of oral corticosteroids
and NSAIDs and to evaluate use of pharmacological prophylaxis strategies.
Methods. Using the Clinical Practice Research Datalink, we explored long-term (3/12 months; 6/12 in sub-
analyses) DMARD, corticosteroid and NSAID prescribing (annually, in the year post-diagnosis and across the
patient’s life course to 15 years post-diagnosis), annual proportion with co-prescribing for prophylaxis of associated
bone (corticosteroids, women only) and gastrointestinal (NSAIDs) comorbidity.
Results. Reported incidence of RA was 5.98 (0.37) per 10 000 person-years and prevalence was 0.91% (0.014) in 2017.
In 71 411 RA patients, long-term DMARD prescribing initially rose post-diagnosis from 41.6% in 1998 to 67.9% in 2009.
Corticosteroid prescribing changed little, overall [22.2% in 1998, 19.1% in 2016; incident risk ratio (IRR) 0.92, 95% CI:
0.82, 1.03] and across the life course from the first to fifteenth year (22.2% to 16.9%). NSAID prescribing declined from
57.7% in 1998, and significantly so from 2008, to 27.1% in 2016 (IRR 0.50, 95% CI: 0.44, 0.56). This continued across the
life course (41.2% to 28.4%). Bone prophylaxis increased to 68.1% in 2008 before declining to 56.4% in 2017; gastro-
intestinal prophylaxis increased from 11.5% in 1998 to 62.6% in 2017. Sub-analyses showed consistent patterns.
Conclusion. Despite modern treatment strategies, corticosteroid prescribing in RA patients remains substantial
and persists beyond 6 months once initiated. Rheumatologists need to determine causes and develop strategies to
reduce corticosteroid use to minimize adverse event occurrence.
Key words: rheumatoid arthritis, electronic health records, disease-modifying anti-rheumatic drugs, cortico-
steroids, trends
Introduction
Modern treatment strategies for RA employ early initiation
of disease-modifying anti-rheumatic drugs (DMARDs) and
short-term concomitant corticosteroids to suppress inflam-
mation (especially in early RA), with NSAIDs offering symp-
tomatic relief [1]. These strategies control inflammation
through a treat-to-target approach, which is associated
with improved patient outcomes [2]. Rheumatologists initi-
ate prescribing and then co-manage patients with general
practitioners (GPs).
Short-term corticosteroid therapy (e.g. 2–3 months in
UK guidelines, 6 months in COBRA-type regimens) is
Rheumatology key messages
. Despite modern RA treatment strategies, long-term prescribing of corticosteroids remains substantial.
. The proportion of RA patients receiving corticosteroids persists across the life course, with suboptimal
bone prophylactic therapy.
. Long-term corticosteroid use has implications for RA comorbidities and infection susceptibility (including COVID-19).
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recommended in early RA, when initiating or changing
DMARDs, with tapered withdrawal of corticosteroids
guided by response and risk factors [1, 3, 4]. Long-term
DMARD therapy should limit inflammation and the
symptoms that underpin continued corticosteroid and
NSAID prescribing. The latter agents may mask uncon-
trolled disease activity and are associated with substan-
tial long-term risks (including cardiovascular, bone and
gastrointestinal disorders) even at low doses, particularly
among the elderly population with comorbidities [5–12].
Guidelines recommend prophylaxis co-prescribing: pro-
ton-pump inhibitors (PPIs) to mitigate against gastro-
intestinal adverse effects of NSAIDs; and bone-
protective treatment when prescribing 7.5 mg of pred-
nisolone daily for 3 months, to prevent osteoporotic
fractures [13–17].
We investigated trends in the pharmacological man-
agement of RA over 20 years to determine whether
modern use of DMARDs and tight control of inflamma-
tion has resulted in less long-term use of corticosteroids
and NSAIDs. We also aimed to assess patterns in
prophylactic therapy co-prescribing.
Methods
We report on a retrospective observational study, fol-
lowing the Strengthening the Reporting of Observational
Studies in Epidemiology guidelines (Supplementary
Table S1, available at Rheumatology online) [18]. The
Clinical Practice Research Datalink (CPRD) Independent
Scientific Advisory Committee approved the protocol
(18_082). There was no patient-public involvement in the
study; dissemination of results to study participants is
not possible.
Data source
We used the April 2018 update of the CPRD GOLD
dataset, containing 17.6 million electronic health records
(EHRs) from 734 UK GP practices. Data undergoes
quality assessment and patients have a comparable
age, sex and ethnicity profile to the national census sta-
tistics and a body mass index distribution to the NHS
Health Survey for England [19–21].
Study population
The eligible population had 1 day of continuous regis-
tration during the study period (1 January 1998–1 April
2018). Patients with a juvenile RA diagnosis or diagnosis
of RA before 18 years of age, of unknown sex or with
records flagged as ‘unacceptable’ quality for research
were excluded. Patients contributed data from the latest
of: the study start date, becoming aged 18 years, and
having 1 year of CPRD good quality (‘up to standard’)
registration [19]. Follow-up ended at the study end date,
last data collection from the GP practice, practice de-
registration, death, or becoming aged 101 years.
We identified diagnoses via Read Version 2 codes
(Supplementary Tables S2 and S3, available at
Rheumatology online). RA codes in CPRD were previ-
ously validated (80% positive predictive value) [22, 23].
To improve certainty of RA diagnosis, we also used
more specific definitions in two sensitivity analyses; 2
RA diagnoses at least 6 months apart; and an RA diag-
nosis with a subsequent DMARD prescription before
April 2018.
To assess whether trends in non-DMARD medication
prescribing were related to their diagnosis of RA, for
each patient with a diagnosis of RA during the study
period, five non-RA patients were randomly selected
and matched by sex and date of birth 65 years from
patients registered at the same practice on the index
date of the RA diagnosis. Non-RA patients had at least
6 months following the index date with no RA diagnosis;
their follow-up ended if RA was subsequently
diagnosed.
Outcomes
The outcomes were the annual RA incidence and preva-
lence, the annual proportion of RA patients receiving
any or long-term DMARD, oral corticosteroid or NSAID
prescribing, variation in oral corticosteroid or NSAID pre-
scribing, and the annual proportion of RA patients
receiving prophylaxis co-prescribing alongside long-term
low or high prednisolone dose and/or NSAID prescrib-
ing. Variation in prescribing was compared by RA diag-
nosis, year, sex, age (18–29 then 10-year bands up to
99), GP practice, and socioeconomic deprivation.
We defined long-term prescribing as 90 days (180
in sub-analyses) total prescription duration within
12 months. Low and high prednisolone dose is defined
in guidelines as <7.5 mg and 7.5 mg, respectively [16].
Socioeconomic deprivation was defined using Index of
Multiple Deprivation quintiles.
Statistical analyses
Baseline cohort characteristics were described for the
prevalent RA, matched RA and non-RA cohorts.
Outcome measures were stratified by sex, age and geo-
graphical area where there was patient representation
from 5 GP practices per area [19]. We reported annual
trends in patient outcomes between 1 January 1997 and
31 December 2017 and calculated age as on 1 July.
Sensitivity analyses ran until 2016 to enable >16 months
of follow-up for the additional coding and prescribing to
occur.
We calculated crude annual and period incidence
rates per 10 000 person-years with 95% CIs for patients
‘at-risk’, i.e. having no RA diagnosis and 1 year of prior
GP registration at the start of that time period [24, 25].
We divided the incident RA patient count by the total
person-years of follow-up. We calculated crude point (1
July of each calendar year) and period prevalence per-
centages with 95% CI. We calculated the annual per-
centage changes (APCs) and performed sensitivity
analyses.
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We identified medication prescriptions using British
National Formulary terms (Supplementary Table S4,
available at Rheumatology online). We calculated annual
mean counts of DMARD, oral corticosteroid and NSAID
prescriptions per person-year with APC, standardized
for follow-up duration, and performed sensitivity analy-
ses. We calculated prescription durations
(Supplementary Data S1, available at Rheumatology on-
line) and the annual and period percentage of RA and
non-RA patients with long-term prescribing, amongst
patients with 90 days follow-up in that time frame (year
or study period). Similarly, for incident patients in each
year, we determined the annual and period percentage
with long-term prescribing [individually and in combin-
ation (e.g. DMARD and corticosteroid)] in the first year
post-diagnosis (1998–2016). For incident patients we
calculated the percentage with long-term prescribing in
each year post-diagnosis up to the fifteenth year (among
patients having 90 days follow-up in each year). In
sub-analyses, we investigated prescribing as above for
patients with 1 and 180 days of prescribing, amongst
patients with 1 and 180 days follow-up in that time
frame (year or study period).
We used Poisson regression with (log) person time as
the offset and GP practice as a random intercept, to
analyse changes in prescribing by calendar year, sex
and age while controlling for the other variables
(Supplementary Data S2, available at Rheumatology on-
line). A sub-analysis included socioeconomic status
where this was recorded. We determined the final coeffi-
cient inclusion using the Akaike information criteria,
Hausman test and comparison of the coefficients and
residual deviance. We used quasi-Poisson regression
where the dispersion parameter was >1 and compari-
son with a zero-inflation model where GP practice was
included as a random intercept.
For patients with 90 days of NSAID medication pre-
scribing in a given year or year post-diagnosis, we cal-
culated the percentage with 90 days of PPI prescribed
in that year. We assessed the annual proportion with
90 days of bone protectant medication prescribing
among women with 90 days of low or high prednisol-
one dose prescribed in that year and having no prior
osteoporosis diagnosis. We assessed the bone protect-
ive agents (bisphosphonates, calcium and vitamin D)
separately and in combination. In period calculations,
the proportions with 90 days of NSAIDs and PPI or
prednisolone and bone protectant in any same year
were calculated.
R Version 3.6.2, Microsoft SQL 2017 and Microsoft
Excel 2016 were used in analyses.
Results
We identified 71 411 RA patients (44 426 with 2 diag-
noses; 45 438 with diagnosis and prescribed DMARD)
of which 41 198 were matched to 205 990 non-RA
patients (Supplementary Fig. S1, available at
Rheumatology online). The median age at diagnosis was
57 (IQR: 23), 70.0% (49 974) were female and 58.1%
(41 509) had socioeconomic deprivation recorded
(Supplementary Table S5, available at Rheumatology
online).
Incidence and prevalence
The period incidence (1998–2017) was 5.57 (0.06) per
10 000 person-years, with 31 768 patients newly diag-
nosed. The annual incidence was 5.01 (0.36) in 1998
and 5.98 (0.37) in 2017, with a peak at 8.48 (0.32) in
2013 (Fig. 1). The mean APC pre-peak was -0.36; þ2.17
and þ2.27 in sensitivity analyses. Incidence among
women was approximately double that of men, 6.92
(0.60) and 3.01 (0.40) in 1998, respectively; 7.86 (0.58)
and 4.33 (0.44) in 2017 (Supplementary Fig. S2, avail-
able at Rheumatology online). Incidence peaked at age
70–79 [10.53 (1.62) in 1998 and 11.09 (1.52) in 2017]
(Supplementary Fig. S3, available at Rheumatology on-
line). There was little regional variation excepting for a
peak in 2016 (20.03, 3.21) in East England
(Supplementary Fig. S4, available at Rheumatology
online).
The period prevalence was 0.89% (0.01)
(Supplementary Table S6, available at Rheumatology on-
line); 0.58% (0.01) in sensitivity analyses. Prevalence
rose from 0.70% (0.013) in 1998 to 0.91% (0.014) in
2017. The APC rose by mean þ1.61 until 2006, before
plateauing (mean þ0.27) until 2013 (þ7.70 in 2013/14),
then rising again. Sensitivity analyses demonstrated
similar results. Prevalence was highest, and rose steep-
est, among patients aged 70–99 (2.21%, 0.05)
(Supplementary Fig. S5, available at Rheumatology on-
line). Differences between women and men remained
stable, 6.92 (0.60) and 3.01 (0.40) in 1998, respectively;
7.86 (0.58) and 4.33 (0.44) in 2017; though there was re-
gional variation in prevalence (Supplementary Figs S6
and S7, available at Rheumatology online).
Trends in DMARD prescribing
During follow-up, 59.6% of RA patients had DMARDs
prescribed and 55.6% received long-term prescribing
(90 days in 1 year) for at least 1 year. The mean pre-
scription count per person-year was 3.00 in 1998 and
7.22 in 2017. The proportion with long-term prescribing
was 31.0% in 1998, rising on a slowing trajectory to
peak at 52.0% in 2013 before falling to 49.3% in 2017
(Fig. 2). Patterns were similar in sub-analyses of 1 and
180 days prescribing in a given year (Supplementary
Figs S8 and S9, available at Rheumatology online).
Annual proportions were higher among patients with
long-term corticosteroid prescribing in a given year
(N¼22 210): 45.4% in 1998 and 56.1% in 2017.
In the year post-diagnosis, 55.2% had long-term
DMARD prescribing. This was 41.6% of patients diag-
nosed in 1998, rising on a slowing trajectory to peak at
67.9% in 2009 before falling to 54.7% in 2016. Patterns
were similar in sub-analyses of 1 and 180 days
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prescribing (Supplementary Figs S10 and S11, available
at Rheumatology online).
Trends in corticosteroid prescribing
During follow-up, 45.1% of RA patients had prescribed
corticosteroids and 32.2% received long-term prescrib-
ing for at least 1 year. The mean count of prescriptions
per person-year was 2.04 in 1998 and 1.89 in 2017.
Among patients prescribed corticosteroids in a given
year, the mean prescription count was 8.03 in 1998 and
8.02 in 2017 (Supplementary Fig. S12, available at
Rheumatology online).
In 1998, 21.0% of RA patients had long-term prescrib-
ing, declining (mean APC -1.54) to 15.5% in 2017.
Findings from sub-analyses were consistent. The decline
was significant between 2013 (IRR 0.87, 95% CI: 0.81,
0.94) and 2017 (IRR 0.75, 95% CI: 0.70, 0.80) (Table 1).
Women were slightly less likely to receive long-term cor-
ticosteroids than men (IRR 0.96, 95% CI: 0.94, 0.97).
Compared with age 18–29 years, prescribing significant-
ly increased with age from 50 (e.g. age 50–59: IRR 1.27,
95% CI: 1.16, 1.39; age 90–99: IRR 1.60, 95% CI: 1.44,
1.78) (Supplementary Fig. S13, available at
Rheumatology online). Socioeconomic deprivation had
no significant effect (data not shown). In the non-RA co-
hort, 3.8% had long-term corticosteroid prescribing dur-
ing follow-up, rising from 0.9% in 1998 to 2.0% in 2017
(Supplementary Fig. S14, available at Rheumatology
online).
In the year post-diagnosis, 22.5% of RA patients had
long-term corticosteroid prescribing. This remained sta-
ble over the study period (22.2% in 1998 and 19.1% in
2016) and findings from sub-analyses were consistent.
Compared with patients aged 18–29 years, the propor-
tion prescribed corticosteroids in the year post-
FIG. 1 Annual incidence and prevalence
(A) Annual incidence rate (N¼ 8 022 645); (B) annual percentage prevalence (N¼ 7 532 147); in 1998–2017 using three
definitions of RA: 1 RA diagnostic code; 2 RA diagnostic codes at least 6 months apart; 1 RA diagnostic code
plus a subsequent DMARD prescription.
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diagnosis increased with age from 50–99 (e.g. age 50–
59: IRR 1.33, 95% CI: 1.09, 1.62; age 90–99: IRR 2.13,
95% CI: 1.65, 2.75). Women were less likely to receive
corticosteroids in the year post-diagnosis (IRR 0.88,
95% CI: 0.85, 0.92). Socioeconomic deprivation had no
significant effect.
Trends in NSAID prescribing
During follow-up, 69.0% of RA patients had prescribed
NSAIDs and 54.4% received long-term prescribing for at
least 1 year. The mean count of prescriptions per
person-year fell from 4.17 in 1998 to 1.96 in 2017. The
proportion with long-term prescribing was 45.9% in
1998 and declined (mean APC -3.10) to 25.1% in 2017,
with sub-analyses showing similar patterns. Compared
with age 18–29 years, prescribing increased significantly
with age until 50–59 (e.g. 50–59: IRR 1.34, 95% CI:
1.28, 1.39) before decreasing with older age. There was
no sex difference but long-term prescribing was greater
among the least socioeconomic deprived patients (quin-
tile 5 compared with 1: IRR 1.04, 95% CI: 1.02, 1.06). In
the non-RA cohort, 19.7% had long-term NSAID pre-
scribing during follow-up, rising from 6.4% in 1998 to
8.4% in 2017.
In the year post-diagnosis, 42.1% had long-term pre-
scribing. This declined from 57.7% in 1998 to 27.1% in
2016, with sub-analyses showing similar patterns. The
decline was significant between 2008 and 2016 (e.g.
2008: IRR 0.76, 95% CI: 0.70, 0.82; 2016: IRR 0.50,
95% CI: 0.44, 0.56). GP practice accounted for slight
variability in prescribing in the year post-diagnosis (vari-
ance: 0.01, standard deviation: 0.11, Hausman P ¼
0.12). There was no sex or socioeconomic deprivation
difference but a trend towards lower prescribing with
increasing age.
Prescribing over the life course
For incident RA patients, 16.5% (n¼ 6604) had 10 years
follow-up and 3.0% (n¼1460) had 15 years. The propor-
tion with long-term DMARD prescribing did not change
significantly over the life course; 54.4% (53.9–55.0%)
and 51.6% (48.9–54.3%) in the first and fifteenth year,
respectively; although there was a declining trend (mean
APC -0.37) (Fig. 3, Supplementary Table S7, available at
Rheumatology online). For corticosteroids the proportion
declined from 22.2% (21.7–22.6%) to 16.9% (14.9–
18.9%) and for NSAIDs from 41.2% (40.6–41.7%) to
28.4% (25.9–30.8%). Most of the decline occurred by
year 3 [mean APC -10.20 (corticosteroids) and -8.66
(NSAIDs)]. Assessments of combination prescribing
showed consistent patterns (Supplementary Fig. S15,
available at Rheumatology online). Sub-analyses showed
similar patterns, excepting a delay in patients receiving
180 days of DMARDs until the second year post-
diagnosis (Supplementary Figs S16 and S17, available
at Rheumatology online).
Prophylaxis co-prescribing
During follow-up, 14 314 women with no evidence of
osteoporosis prior to RA had long-term prednisolone in
a year. Of these, in 1998, 2.1% were prescribed long-
term bisphosphonate; 11.8% calcium and vitamin D and
13.4% calcium and vitamin D or bisphosphonate, rising
to 26.8%; 49.8% and 56.4% in 2017 (Fig. 4). Long-term
bisphosphonate prescribing rose steeply to 49.4% in
2007 before slowly declining, especially among patients
aged 60 years (Supplementary Fig. S18, available at
Rheumatology online). The patterns were comparable
for high (n¼5952) and low (n¼ 13 061) prednisolone
dose cohorts (Supplementary Figs. S19 and S20, avail-
able at Rheumatology online), [e.g. 59.9% (95% CI:
54.9, 65.0) and 55.4% (95% CI: 52.8, 58.1) with calcium
FIG. 2 The annual proportion with long-term prescribing
The annual percentage (1998–2017) of patients with 90 days annual prescribing: all RA patients (N¼68 939) and in
the first year post-diagnosis (N¼ 29 918).
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and vitamin D or bisphosphonate in 2017, respectively].
Among 38 480 patients with long-term NSAID prescrib-
ing, 50.5% had PPI prescribed long-term in the same
year. This rose (mean APC þ9.52) from 11.5% in 1998
to 62.6% in 2017. The APC declined over time from
þ19.82 in 1998/9 to -1.75 in 2016/17.
Discussion
This study demonstrated little change in corticosteroid
prescribing in RA patients in the UK by GPs, and no
change in the year post-diagnosis despite modern treat-
ment strategies. Although the decline in corticosteroid
prescription was significant across the first 3 years
post-diagnosis, prescribing remained substantial 3 years
post-diagnosis (17.9%) and persisted for the duration of
the study, particularly in older age groups. NSAID pre-
scribing halved among RA patients, predominantly
driven by changing practice for newly diagnosed
patients, though remained substantial (34.3% at 3 years
post-diagnosis). Additionally, the increased DMARD pre-
scribing in the year post-diagnosis plateaued from 2009.
TABLE 1 Adjusted incident risk ratios for having long-term medication prescribing. Adjusted incident risk ratios (IRRs) for
having 90 days annual medication prescribing (all RA patients and in the year post-diagnosis)†
Adjusted IRR (95% CI)
Corticosteroid NSAID
All RA patients
(N 5 68 939)
First year post-diag-
nosis (N 5 30 799)
All RA patients
(N 5 68 939)
First year post-
diagnosis
(N 5 30 799)†
Calendar year
1998 1 1 1 1
1999 1.02 (0.95, 1.10) 1.02 (0.89, 1.17) 1 (0.96, 1.05) 0.99 (0.91, 1.08)
2000 1.06 (0.99, 1.13) 1.03 (0.90, 1.17) 0.97 (0.92, 1.01) 0.96 (0.89, 1.05)
2001 1.04 (0.97, 1.12) 0.97 (0.85, 1.10) 0.95 (0.91, 0.99) 0.91 (0.84, 0.99)
2002 1.02 (0.96, 1.08) 1.00 (0.89, 1.12) 0.94 (0.90, 0.97) 0.94 (0.86, 1.01)
2003 1.01 (0.95, 1.07) 1.05 (0.94, 1.18) 0.92 (0.88, 0.95)* 0.89 (0.82, 0.97)
2004 1.00 (0.94, 1.06) 1.00 (0.89, 1.12) 0.92 (0.89, 0.95)* 0.95 (0.88, 1.03)
2005 0.98 (0.92, 1.04) 1.03 (0.92, 1.15) 0.95 (0.92, 0.98) 0.91 (0.85, 0.99)
2006 0.96 (0.91, 1.02) 1.10 (1.00, 1.22) 0.89 (0.86, 0.92)* 0.82 (0.76, 0.89)
2007 0.96 (0.91, 1.02) 1.24 (1.09, 1.41) 0.84 (0.81, 0.88)* 0.83 (0.76, 0.90)
2008 0.96 (0.90, 1.01) 1.18 (1.07, 1.31) 0.81 (0.78, 0.84)* 0.76 (0.70, 0.82)*
2009 0.94 (0.89, 1.00) 1.19 (1.06, 1.33) 0.77 (0.74, 0.80)* 0.68 (0.62, 0.74)*
2010 0.93 (0.87, 0.99) 1.18 (1.08, 1.30) 0.74 (0.71, 0.77)* 0.70 (0.64, 0.76)*
2011 0.92 (0.87, 0.98) 1.13 (1.01, 1.26) 0.73 (0.70, 0.75)* 0.64 (0.58, 0.70)*
2012 0.91 (0.85, 0.98) 1.16 (1.04, 1.31) 0.70 (0.67, 0.72)* 0.60 (0.54, 0.66)*
2013 0.87 (0.81, 0.94)* 0.77 (0.69, 0.86) 0.68 (0.66, 0.70)* 0.56 (0.51, 0.61)*
2014 0.83 (0.77, 0.89)* 0.75 (0.68, 0.83) 0.66 (0.64, 0.68)* 0.48 (0.44, 0.53)*
2015 0.81 (0.76, 0.86)* 0.78 (0.68, 0.90) 0.65 (0.62, 0.67)* 0.53 (0.47, 0.59)*
2016 0.80 (0.75, 0.85)* 0.92 (0.82, 1.03) 0.63 (0.61, 0.65)* 0.50 (0.44, 0.56)*
2017 0.75 (0.70, 0.80)* 0.57 (0.54, 0.60)*
Sex
Male 1 1 1 1
Female 0.96 (0.94, 0.97)* 0.88 (0.85, 0.92)* 1 (0.99, 1.01) 1.02 (0.99, 1.05)
Age group
18–29 1 1 1 1
30–39 1.07 (0.97, 1.19) 1.05 (0.84, 1.30) 1.15 (1.10, 1.20)* 1.13 (1.03, 1.25)
40–49 1.05 (0.95, 1.15) 1.03 (0.83, 1.27) 1.32 (1.26, 1.37)* 1.17 (1.07, 1.29)
50–59 1.27 (1.16, 1.39)* 1.33 (1.09, 1.62) 1.34 (1.28, 1.39)* 1.16 (1.06, 1.27)
60–69 1.67 (1.52, 1.84)* 1.73 (1.42, 2.11)* 1.24 (1.20, 1.30)* 1.09 (1.00, 1.20)
70–79 2.08 (1.90, 2.27)* 2.35 (1.93, 2.85)* 0.99 (0.95, 1.04) 0.91 (0.83, 1.00)
80–89 2.18 (1.99, 2.40)* 2.6 (2.12, 3.19)* 0.74 (0.70, 0.77)* 0.72 (0.65, 0.81)*
90–99 1.60 (1.44, 1.78)* 2.13 (1.65, 2.75)* 0.56 (0.52, 0.61)* 0.75 (0.61, 0.91)
Note: adjusted for calendar year, sex and age group as appropriate. † GP practice included as a random intercept.
*P < 0.001.
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Improvements in prophylaxis co-prescribing remain sub-
optimal. In elderly and comorbid populations treated
with DMARD immune suppressants, persistent cortico-
steroid exposure with attendant immune suppression is
particularly concerning and pertinent in the context of in-
fectious diseases including COVID-19 and tuberculosis
[26].
Our prevalence estimates of RA of 0.5–1%, higher
among women and increasing with age, are consistent
with older studies [25, 27]. Abishek et al. using CPRD
data, reported lower incidence and prevalence (1990–
2014) and declining incidence, which we did not find,
especially in sensitivity analyses [25]. This may be due
to differences in defining RA. In the UK, GPs receive
payment for using specific RA codes to maintain a
registry of RA patients and perform annual review and
risk assessments [28]. Some of these codes were not
used to define RA by Abishek et al. although they were
in our study. This would make some patients, and par-
ticularly those diagnosed in rheumatology clinics and
annually reviewed by GPs, less likely to be included in
the previous study. Further, we included codes naming
RA in specific joints and excluded patients without 1
year of ‘up to standard’ registration.
The proportion of patients with DMARD, corticosteroid
and NSAID prescribed during follow-up was comparable
to older studies [29–32]. However, we show that cortico-
steroid prescribing has persisted in the current treat-to-
target era, even after the first year of diagnosis. While
some therapy strategies continue corticosteroid pre-
scribing beyond the 3- and 6-month definitions of long-
term used here [33], we found persistence even 15 years
post-diagnosis. As observed in other immune-mediated
inflammatory diseases (e.g. polymyalgia rheumatica),
corticosteroids may relieve symptoms (e.g. regional
musculoskeletal complaints) not necessarily relating to
activity of the index disease [34, 35]. This likely perpetu-
ates corticosteroid prescribing despite guidelines and
trial-based evidence of associated diabetes, hyperten-
sion and cardiovascular disease risk in RA patients [9,
10, 12]. It may also mask symptoms of poor RA disease
control. While the difficulties in corticosteroid tapering,
including adrenal suppression, are well recognized,
there are reported favourable outcomes from discontinu-
ing corticosteroids after 34 weeks in early RA [36].
Intramuscular corticosteroids provide a fixed tapered
dose and may be useful for short-term use [4].
Clinicians need to recognise the unmet need for pain
control, which can contribute to disease activity scores,
and assess whether joint pain is due to RA or other con-
ditions [37–39].
While studies have reported low bone-protectant co-
prescribing (<15% between 1991 and 1997) and GI-
protectant co-prescribing (10% between 2001 and
2003) in the general population [40, 41], this study
shows temporal trends in RA patients. Declining NSAID
prescribing among RA patients and increasing GI
prophylaxis (especially from 2005) reflects rising aware-
ness of NSAID toxicity through the early 2000s and the
withdrawal of rofecoxib [42–44]. However, the rate of
increasing GI prophylaxis co-prescribing has slowed
and reversed in 2017. Initial increases in bone prophy-
laxis reversed from 2008, with declining bisphosphonate
co-prescribing while vitamin D-calcium co-prescribing
plateaued around 50%. A similar trend in bisphospho-
nates was reported in Canada, USA and Australia fol-
lowing safety concerns [45–47]. With growing RA
prevalence among the elderly who are most susceptible
to multi-morbidity [48], renewed efforts to increase bone
and GI prophylaxis are crucial, and must target extant
as well as incident RA cases.
Study strengths included long-term follow-up of a
large population-based cohort. Sensitivity analyses
improved the specificity of the RA case definition and
confirmed the robustness of the primary study findings.
Sub-analyses assessing 180 days prescribing in a year
FIG. 3 The proportion with long-term prescribing in the 1–15 years post-diagnosis
Percentage of incident RA patients with 90 days annual prescribing in the 1–15 years post-diagnosis, with 95% CI
(N¼30 807).
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enabled conservative estimates that confirmed findings.
The matched non-RA cohort facilitated in discerning RA-
specific prescribing patterns.
Study limitations include those common to EHR-
based studies [49, 50]. RA definitions were affected by
coding practices, including payment introduced for GPs
in the UK in 2013, for diagnostic coding of RA patients
[28], which correlates with a peak in incidence in this
study, which we attempted to address with sensitivity
analyses. It may have triggered incident coding of
prevalent cases, where records had undifferentiated
arthritis coded or free-text RA diagnostic references.
The higher prevalence estimates post-2013 may
therefore be more accurate. While data was utilized
from a representative sample of UK GP practices, pre-
scribing may differ between settings and countries.
Importantly CPRD does not capture secondary care pre-
scribing of conventional or biologic-DMARDs or intra-
venous bisphosphonates and denusomab so DMARDs
and bone protectants were underestimated in this study.
DMARD prescribing may have continued to rise through
biologic availability in secondary care; however, these
are typically second-line therapeutics and GP DMARD
prescribing did not change across the life course, sug-
gesting that the apparent plateau from 2009 requires in-
vestigation. Intramuscular, intravenous and intra-articular
FIG. 4 The annual proportion with RA medication and protectant
The percentage of RA patients with 90 days of annual RA medication and protectant (1998–2017): (A) corticosteroid
and bone protectant (bisphosphonate, calcium and vitamin D) (N¼ 14 314); (B) NSAID and PPI (N¼ 38 480).
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corticosteroids (which may also be given in secondary
care) were not assessed, so the corticosteroid burden is
also higher than we report and their use may have
changed over time. Further, we did not examine all anal-
gesics that may be used in RA management.
Unascertainable prescription durations were set at
90 days, which may overestimate use given that the
mode duration was 28 days. However, this affected
<3% prescriptions, findings were consistent in sub-
analyses of 180 days prescribing, and this should not
affect interpretation of change over time. These long-
term prescribing definitions should also allow for unused
prescriptions, given the mode prescription duration. We
did not examine change in corticosteroid dosages,
which would inform understanding of exposure and
medication tapering; however, toxicity is increased for
all doses [8–11] and we showed prescribing for 15 years
post-diagnosis, beyond the recommended duration for
tapering. We could not distinguish where DMARDs were
unsuitable or ineffective and long-term corticosteroids or
NSAIDs formed part of an informed therapeutic ap-
proach, but such cases are uncommon [51] and
DMARD prescribing was more common among RA
patients with long-term corticosteroids.
Despite modern treatment strategies and increased
DMARD prescription, long-term corticosteroid prescribing in
RA patients remains substantial, especially among elderly
patients, and persists once initiated. Long-term corticoster-
oid prescribing has clear implications for RA comorbidities
and susceptibility to infection (of particular relevance during
the COVID-19 pandemic). Rheumatologists need to under-
stand the causes of persistent prescribing and develop al-
ternative strategies of pain management.
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Johansson S, Wallander M-A. Rheumatoid arthritis in UK
primary care: incidence and prior morbidity. Scand J
Rheumatol 2009;38:173–7.
24 Lewis JD, Bilker WB, Weinstein RB, Strom BL. The
relationship between time since registration and
measured incidence rates in the General Practice
Research Database. Pharmacoepidemiol Drug Saf 2005;
14:443–51.
25 Abhishek A, Doherty M, Kuo CF et al. Rheumatoid
arthritis is getting less frequent—results of a nationwide
population-based cohort study. Rheumatology (Oxford)
2017;56:736–44.
26 Fauci AS. Mechanisms of the immunosuppressive and
anti-inflammatory effects of glucocorticosteroids. J
Immunopharmacol 1978;1:1–25.
27 Alamanos Y, Drosos AA. Epidemiology of adult
rheumatoid arthritis. Autoimmun Rev 2005;4:130–6.




2012-13 (10 February 2020, date last accessed).
29 Black RJ, Joseph RM, Brown B et al. Half of U.K.
patients with rheumatoid arthritis are prescribed oral
glucocorticoid therapy in primary care: a retrospective
drug utilisation study. Arthritis Res Ther 2015;17:375.
30 Edwards CJ, Campbell J, van Staa T, Arden NK.
Regional and temporal variation in the treatment of
rheumatoid arthritis across the UK: a descriptive
register-based cohort study. BMJ Open 2012;2:e001603.
31 Ogdie A, Yu Y, Haynes K et al. Risk of major
cardiovascular events in patients with psoriatic arthritis,
psoriasis and rheumatoid arthritis: a population-based
cohort study. Ann Rheum Dis 2015;74:326–32.
32 Fardet L, Petersen I, Nazareth I. Prevalence of long-term
oral glucocorticoid prescriptions in the UK over the past
20 years. Rheumatology (Oxford) 2011;50:1982–90.
33 Boers M, Verhoeven AC, Markusse HM et al.
Randomised comparison of combined step-down pred-
nisolone, methotrexate and sulphasalazine with










niversity of Leeds user on 15 April 2021
sulphasalazine alone in early rheumatoid arthritis. 1997;
350:309–18.
34 Apostolopoulos D, Morand EF. It hasn’t gone away: the
problem of glucocorticoid use in lupus remains.
Rheumatology (Oxford) 2017;56(suppl_1):i114–i22.
35 Yates M, Watts R, Swords F, MacGregor A. Glucocorticoid
withdrawal in polymyalgia rheumatica: the theory versus
the practice. Clin Exp Rheumatol 2017;35:1–2.
36 Stouten V, Westhovens R, Pazmino S; on behalf of the
CareRA study group et al. Effectiveness of different
combinations of DMARDs and glucocorticoid bridging in
early rheumatoid arthritis: two-year results of CareRA.
2019;58:2284–94.
37 Studenic P, Radner H, Smolen JS, Aletaha DJA.
Discrepancies between patients and physicians in their
perceptions of rheumatoid arthritis disease activity.
Arthritis Rheum 2012;64:2814–23.
38 Mathieu S, Couderc M, Pereira B et al. Prevalence of
migraine and neuropathic pain in rheumatic diseases. J
Clin Med 2020;9:1890.
39 Studenic P, Smolen JS, Aletaha D. Near misses of ACR/
EULAR criteria for remission: effects of patient global
assessment in Boolean and index-based definitions. Ann
Rheum Dis 2012;71:1702–5.
40 Van Staa T-P, Leufkens H, Abenhaim L et al. Use of oral
corticosteroids in the United Kingdom. QJM 2000;93:
105–11.
41 Walsh L, Wong C, Pringle M, Tattersfield A. Use of oral
corticosteroids in the community and the prevention of
secondary osteoporosis: a cross sectional study. BMJ
1996;313:344–6.
42 Fischer LM, Schlienger RG, Matter CM, Jick H, Meier
CR. Discontinuation of nonsteroidal anti-inflammatory
drug therapy and risk of acute myocardial infarction.
Arch Intern Med 2004;164:2472–6.
43 Bresalier R, Sandler R, Quan H et al. Cardiovascular
events associated with rofecoxib in a colorectal adenoma
chemoprevention trial. N Engl J Med 2005;352:1092–102.
44 Merck & Co., Inc. Merck announces voluntary worldwide
withdrawal of Vioxx [news release; 30 September 2004]
2004. http://www.merck.com/newsroom/vioxx/pdf/vioxx_
press_release_final.pdf (10 February 2020, date last
accessed).
45 Hayes KN, Ban J, Athanasiadis G, Burden AM,
Cadarette S. Time trends in oral bisphosphonate
initiation in Ontario, Canada over 20 years reflect drug
policy and healthcare delivery changes. Osteoporos Int
2019;30:2311–9.
46 Kim SC, Kim DH, Mogun H et al. Impact of the US Food
and Drug Administration’s safety-related announcements
on the use of bisphosphonates after hip fracture. J Bone
Miner Res 2016;31:1536–40.
47 Sambrook PJ, Nordin B, Goss A. Impact of adverse
news media on prescriptions for osteoporosis: effect on
fractures and mortality. Med J Aust 2011;194:51–2.
48 Barnett K, Mercer SW, Norbury M et al. Epidemiology of
multimorbidity and implications for health care, research,
and medical education: a cross-sectional study. Lancet
2012;380:37–43.
49 Crossfield SS, Lai LYH, Kingsbury SR et al. Variation in
methods, results and reporting in electronic health
record-based studies evaluating routine care in gout: a
systematic review. PloS One 2019;14:e0224272.
50 Tate AR, Dungey S, Glew S et al. Quality of recording of
diabetes in the UK: how does the GP’s method of
coding clinical data affect incidence estimates? Cross-
sectional study using the CPRD database. BMJ Open
2017;7:e012905.
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